Successful therapeutic vaccination with Vacc-4x

Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection Bionor Pharma announced today presentation of data from its international multicenter double-blinded placebo-controlled phase IIB study at the IAS conference in Rome. As previously communicated, a statistically significant difference in viral load set point was observed between the Vacc-4x …

Read more

Vacc-4x phase IIB study accepted as a poster at the IAS conference

Oslo, 21.06.2011 – An abstract of Bionor Pharma’s Vacc-4x phase IIB study has been accepted as poster at the IAS conference in Rome 17-20 July 2011. Bionor Pharma has been informed that an abstract of the Vacc-4x phase IIB study has been accepted to be presented as a poster at the 6(th) IAS Conference on …

Read more

NMA (SLV) approve testing of Vacc-4x using a nasal administration system

Oslo, 16.06.2011 – Oslo University Hospital has received approval to test Bionor Pharma’s HIV-vaccine, Vacc-4x, using a nasal administration system Oslo University Hospital has notified Bionor Pharma of approval from the Norwegian Medicines Agency (Statens Legemiddelverk) for an Investigator Initiated Study (IIS) to be conducted at Oslo University Hospital, testing the effect of Bionor Pharma’s …

Read more